Contents 3 min read
Claim and source comparison
The Pizzi 1993, Nakamura 2001, Elston 2014 and Tian 2008 abstracts were compared with the FDA’s dated letter. This limited source reading is not a comprehensive clinical or independent medical review.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Cell / laboratory study
Pizzi et al. (1993) reported potentiation of mGluR responses by aniracetam in rat cell cultures. This does not support an mGluR1/5 antagonism claim; it is not a human anxiety or neurodegeneration treatment result.
Protection and receptor responses in rat cell cultures do not establish effects in the human brain, clinical neurodegeneration treatment or mGluR1/5 antagonism.
Source 4 · Abstract read
Animal study
Nakamura and Kurasawa (2001) tested aniracetam in three mouse anxiety models. Findings suggest cholinergic, dopaminergic and serotonergic involvement; they do not establish human anxiety treatment or greater safety than benzodiazepines.
Behavior and antagonist experiments in mouse models do not demonstrate treatment of human anxiety disorders, increased creativity or superior safety to benzodiazepines.
Source 5 · Abstract read
Animal study
Elston et al. (2014) found no significant group differences in learning, anxiety or other assessed behaviors with oral aniracetam at 50 mg/kg in healthy C57BL/6J mice.
A null mouse experiment does not establish absence of effects in humans; positive animal models likewise cannot establish cognitive enhancement in healthy humans. The 50 mg/kg amount is not a human dose.
Source 7 · Abstract read
Human pharmacokinetic study
Tian et al. (2008) found a parent-aniracetam plasma half-life of about 0.5 hours in 20 healthy men taking 400 mg while fasting. Metabolite duration and perceived effects are separate concepts; this does not establish a need for 2–3 daily doses.
Approximately 0.5 hours describes plasma elimination of parent aniracetam. This bioequivalence experiment between two formulations does not establish clinical efficacy, metabolite duration, personal timing or a need for a fatty meal.
Source 6 · Abstract read
Regulatory scientific assessment
The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.
This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.
Source 8 · Official summary read
2026-11-11 correction: Cell and mouse experiments were separated from human treatment; a null study in healthy mice was added. Parent-compound half-life was not presented as metabolite or effect duration. Unverified safety, meal and country-approval claims were removed.
What is Aniracetam?
Aniracetam is a fat-soluble racetam. Memory and anxiety mechanisms have mostly been studied preclinically; efficacy and a safe regimen in healthy people have not been established.
Mechanism of Effect
Pizzi et al. (1993) reported potentiation of mGluR responses by aniracetam in rat cell cultures. This does not support an mGluR1/5 antagonism claim; it is not a human anxiety or neurodegeneration treatment result.
Protection and receptor responses in rat cell cultures do not establish effects in the human brain, clinical neurodegeneration treatment or mGluR1/5 antagonism.
Nakamura and Kurasawa (2001) tested aniracetam in three mouse anxiety models. Findings suggest cholinergic, dopaminergic and serotonergic involvement; they do not establish human anxiety treatment or greater safety than benzodiazepines.
Behavior and antagonist experiments in mouse models do not demonstrate treatment of human anxiety disorders, increased creativity or superior safety to benzodiazepines.
Clinical Evidence
Elston et al. (2014) found no significant group differences in learning, anxiety or other assessed behaviors with oral aniracetam at 50 mg/kg in healthy C57BL/6J mice.
A null mouse experiment does not establish absence of effects in humans; positive animal models likewise cannot establish cognitive enhancement in healthy humans. The 50 mg/kg amount is not a human dose.
Tian et al. (2008) found a parent-aniracetam plasma half-life of about 0.5 hours in 20 healthy men taking 400 mg while fasting. Metabolite duration and perceived effects are separate concepts; this does not establish a need for 2–3 daily doses.
Approximately 0.5 hours describes plasma elimination of parent aniracetam. This bioequivalence experiment between two formulations does not establish clinical efficacy, metabolite duration, personal timing or a need for a fatty meal.
Dose information and research limits
There is no validated cognitive or anxiety dose of aniracetam for healthy people. Absorption while fasting was measured in human pharmacokinetic research; it does not establish that a fatty meal is mandatory or that adding choline prevents headaches.
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Safety and Side Effects
The accessed pharmacokinetic and limited clinical data do not establish long-term safe use or the safety of drug combinations. Added choline has not been shown to prevent adverse effects; absence of an interaction record is not evidence of safety.
The FDA’s 2019 Peak Nootropics warning letter addresses marketed treatment claims for aniracetam, oxiracetam and pramiracetam products; it does not recognize those products as approved safe and effective treatments.
This is a dated US regulatory record about the named seller and claims; it is not a current global approval map or a clinical experiment measuring a particular adverse-event rate. Online sale does not establish safety or approval.
Sources
- Nakamura K, Tanaka Y. (2001). Antidepressant-like effects of aniracetam in aged rats and its mode of action. Psychopharmacology, 158(2), 205–212. PubMed · PMID 11702095
- Ito I, et al. (1990). Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam. Journal of Physiology, 424, 533–543. PubMed · PMID 1975272
- Cumin R, et al. (1982). Effects of the novel compound aniracetam (Ro 13-5057) upon impaired learning and memory in rodents. Psychopharmacology, 78(2), 104–111. PubMed · PMID 6817363
- Pizzi M, et al. (1993). Attenuation of excitatory amino acid toxicity by metabotropic glutamate receptor agonists and aniracetam in primary cultures of cerebellar granule cells. Journal of Neurochemistry, 61(2), 683–9. https://doi.org/10.1111/j.1471-4159.1993.tb02173.x PubMed · PMID 8101561
- Nakamura K, et al. (2001). Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. European Journal of Pharmacology, 420(1), 33–43. https://doi.org/10.1016/s0014-2999(01)01005-6 PubMed · PMID 11412837
- Tian Y, et al. (2008). Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung, 58(10), 497–500. https://doi.org/10.1055/s-0031-1296547 PubMed · PMID 19025058
- Elston TW, et al. (2014). Aniracetam does not alter cognitive and affective behavior in adult C57BL/6J mice. PLoS One, 9(8), e104443. https://doi.org/10.1371/journal.pone.0104443 PubMed · PMID 25099639
- US Food and Drug Administration. (2019). Warning Letter: Peak Nootropics LLC aka Advanced Nootropics. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/peak-nootropics-llc-aka-advanced-nootropics-557887-02052019 US Food and Drug Administration
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Aniracetam is a fat-soluble racetam. Memory and anxiety mechanisms have mostly been studied preclinically; efficacy and a safe regimen in healthy people have not been established.
There is no validated cognitive or anxiety dose of aniracetam for healthy people. Absorption while fasting was measured in human pharmacokinetic research; it does not establish that a fatty meal is mandatory or that adding choline prevents headaches.
The accessed pharmacokinetic and limited clinical data do not establish long-term safe use or the safety of drug combinations. Added choline has not been shown to prevent adverse effects; absence of an interaction record is not evidence of safety.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
Tian et al. (2008) found a parent-aniracetam plasma half-life of about 0.5 hours in 20 healthy men taking 400 mg while fasting. Metabolite duration and perceived effects are separate concepts; this does not establish a need for 2–3 daily doses.